The therapeutic community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a significant substantial